156 related articles for article (PubMed ID: 12954580)
1. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer.
Tambaro R; Greggi S; Iaffaioli RV; Rossi A; Pisano C; Manzione L; Ferrari E; Di Maio M; Iodice F; Casella G; Laurelli G; Pignata S
Ann Oncol; 2003 Sep; 14(9):1406-11. PubMed ID: 12954580
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of Doxil and vinorelbine in patients with advanced malignancies.
Laufman LR; Spiridonidis CH; Jones JJ; Rhodes V; Rossi K; Wallace K
Cancer Invest; 2004; 22(3):344-52. PubMed ID: 15493354
[TBL] [Abstract][Full Text] [Related]
4. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
[TBL] [Abstract][Full Text] [Related]
5. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
Subramanyan S; Abeloff MD; Bond SE; Davidson NE; Fetting JH; Gordon GB; Kennedy MJ
Cancer Chemother Pharmacol; 1999; 43(6):497-502. PubMed ID: 10321510
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer.
Verhaar-Langereis M; Karakus A; van Eijkeren M; Voest E; Witteveen E
Int J Gynecol Cancer; 2006; 16(1):65-70. PubMed ID: 16445612
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.
Bakker M; Groen HJ; Smit EF; Smeets J; Riggi M; Postmus PE
Br J Cancer; 1995 Dec; 72(6):1547-50. PubMed ID: 8519675
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.
Gordon AN; Granai CO; Rose PG; Hainsworth J; Lopez A; Weissman C; Rosales R; Sharpington T
J Clin Oncol; 2000 Sep; 18(17):3093-100. PubMed ID: 10963637
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
Saeki T; Takashima S; Ogita M; Tabei T; Adachi I; Tamura K; Takatsuka Y; Kanda K
Breast Cancer; 2006; 13(2):159-65. PubMed ID: 16755111
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma.
Katsaros D; Oletti MV; Rigault de la Longrais IA; Ferrero A; Celano A; Fracchioli S; Donadio M; Passera R; Cattel L; Bumma C
Ann Oncol; 2005 Feb; 16(2):300-6. PubMed ID: 15668288
[TBL] [Abstract][Full Text] [Related]
16. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Keller AM; Mennel RG; Georgoulias VA; Nabholtz JM; Erazo A; Lluch A; Vogel CL; Kaufmann M; von Minckwitz G; Henderson IC; Mellars L; Alland L; Tendler C
J Clin Oncol; 2004 Oct; 22(19):3893-901. PubMed ID: 15459210
[TBL] [Abstract][Full Text] [Related]
19. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
Pignata S; Scambia G; Savarese A; Breda E; Scollo P; De Vivo R; Rossi E; Gebbia V; Natale D; Del Gaizo F; Naglieri E; Ferro A; Musso P; D'Arco AM; Sorio R; Pisano C; Di Maio M; Signoriello G; Annunziata A; Perrone F;
BMC Cancer; 2006 Aug; 6():202. PubMed ID: 16882344
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
Fracasso PM; Blum KA; Tan BR; Fears CL; Bartlett NL; Arquette MA; Clark RS
Cancer; 2002 Nov; 95(10):2223-9. PubMed ID: 12412177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
